Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients

Expert Opinion on Drug Delivery

Volumn 4, Issue 2, 2007, Pages 91-94

  Westerman, E M ^a   Heijerman, H G M ^a   Frijlink, H W ^b  

^a HAGA HOSPITAL   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Antibiotics; Cystic fibrosis; Dry powder inhalation; Pulmonary drug delivery; Wet nebulisation

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; DORNASE ALFA; GENTAMICIN; TOBRAMYCIN;

AEROSOL; ANTIBIOTIC RESISTANCE; BRONCHIECTASIS; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG TISSUE LEVEL; DRY POWDER; EDITORIAL; HUMAN; INCIDENCE; LONG TERM CARE; NEBULIZATION; NEBULIZER; PARTICLE SIZE; PHYSICAL CHEMISTRY; PILOT STUDY; PSEUDOMONAS AERUGINOSA; REPRODUCIBILITY; RISK REDUCTION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEMS; HUMANS; NEBULIZERS AND VAPORIZERS; POWDERS; PSEUDOMONAS INFECTIONS;

EID: 33847777944     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.4.2.91     Document Type: Editorial

References (17)

1. Cystic Fibrosis Foundation National Patient Registry Annual Data Report 2000 and 2004. Bethesda (MD): Cystic Fibrosis Foundation (2001,2005)
2. KULICH M, ROSENFELD M, GOSS CH, WILMOTT R. Improved survival among young patients with cystic fibrosis. J. Pediatr. (2003) 142:631-636.
3. RAMSEY BW, PEPE MS, QUAN JM et al: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. (1999) 340:23-30.
4. TIDDENS HA: Detecting early structural lung damage in cystic fibrosis. Pediatr. Pulmonol. (2002) 34:228-231.
5. LE BRUN PP, DE BOER AH, GJALTEMA D, HAGEDOORN P, HEIJERMAN HG, FRIJLINK HW. Inhalation of tobramycin in cystic fibrosis. Past 1: the choice of a nebulizer. Int. J. Pharm. (1999) 189:205-214.
6. BOE J, DENNIS JH, O'DRISCOLL BR et al.: European Respiratory Society Guidelines on the use of nebulizers. Eur. Respir. J. (2001) 18:228-242.
7. LE BRUN PP, VINKS, AA, TOUW DJ et al.: Can tobramycin inhalation be improved with a jet nebulizer? Ther. Drug. Monit. (1999) 21:618-24
8. BYRNE NM, KEAVEY PM, PERRY JD, GOULD FK, SPENCER DA: Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis. Arch. Dis. Child. (2003) 88:715-718.
9. KASTELIK JA, WRIGHT GA, AZIZ I et al.: A widely available method for the assessment of aerosol delivery in cystic fibrosis. Pulm. Pharmacol. Ther. (2002) 15:513-519
10. MARSDEN RJ, CONWAY SP, DODD ME et al.: Comparison of the HaloLite adaptive aerosol delivery (AAD®) system with a high output nebuliser system in cystic fibrosis patients. Thorax (2002) 57:48-94 (P114).
11. NEWHOUSE MT, HIRST PH, DUDDU SP et al.: Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest (2003) 124:360-366.
12. GOLDMAN JM, BAYSTON SM, O'CONNOR S, MEIGH RE: Inhaled micronised gentamicin powder: a new delivery system. Thorax (1990) 45:939-940.
13. CROWTHER LABIRIS NR, HOLBROOK AM, CHRYSTYN H, MACLEOD SM, NEWHOUSE MT: Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. Am. J. Respir. Crit. Care Med. (1999) 160:1711-1716.
14. LE BRUN PP, DE BOER AH, MANNES GP et al.: Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur. J. Pharm. Biopharm. (2002) 54:25-32.
15. WESTERMAN EM, DE BOER AH, LE BRUN PP et al.: Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J. Cyst. Fibros. (2006) doi:10.1016/j.jcf.2006.10.010 (In press).
16. DE BOER AH, HAGEDOORN P, WESTERMAN EM, LE BRUN PP, HEIJERMAN HG, FRIJLINK HW: Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer®) for high powder doses. Eur. J. Pharm. Sci. (2006) 28:171-178.
17. WESTERMAN EM, DE BOER AH, LE BRUN PP, TOUW DJ, FRIJLINK HW, HEIJERMAN HG: Dry powder inhalation of colistin sulphomethate in healthy volunteers: a pilot study. Int. J. Pharmaceut. (2006) doi: 10.1016/ j.ijpharm.2006.11.021 (In press).